Dr. Christina Eich

Postdoctoral Researcher

Vakgebied(en)

  • Tumour Immunology, Immunology, Immunotherapy
  • Molecular Biology
  • (Molecular) Imaging
  • Hematopoietic stem cells
  • Transcription Factors
  • Immunotherapy

Introductie

 Christina Eich graduated from the University of Bonn and joined the Tumour Immunology Department at the Radboud University in Nijmegen (The Netherlands) in 2007 for her PhD. During her PhD project and first year of postdoctoral research she explored how adhesion receptor signals orchestrate adhesion/trafficking of immune cells in vivo. She applied microscopy and proteomics to investigate how the molecular organization of the cell surface influences cell adhesion by studying the model adhesion receptor LFA-1. Her research demonstrated that nanoscale changes in the lipid composition of the plasma membrane affect receptor mobility and consequently immune cell function. Moreover, she demonstrated for the first time that LFA-1 interacting proteins change during cell differentiation, differentially regulating LFA-1 function in immune cells. During her second postdoctoral at the Erasmus Stem Cell Institute, Department of Cell biology, Erasmus Medical Center Rotterdam (The Netherlands), she studied the molecular events that regulate the emergence of the long-lived hematopoietic stem cells (HSC), with particular focus on gene regulation and transcription factors. She exploited time-lapse confocal microscopy and RNA sequencing to study the expression of crucial transcription factors for HSC generation in the mouse embryo. This research focused on how fluctuations in gene expression determine cell identity and cell fate in the context of HSC generation and aimed for a better understanding of the early processes that lead to the generation of HSCs. In her current position as a senior postdoctoral at the Translational Nanobiomaterials and Imaging group in the Radiology Department at the LUMC she aims to apply the nanotechnology and imaging platform established in the group to target cells in vivo (tumour cells, immune cells and HSCs) to deliver therapeutics, imaging agents or gene editing tools for the treatment of cancer, combined with in vivo molecular imaging. 


Contactgegevens

Leids Universitair Medisch Centrum
Gebouw 1

Albinusdreef 2
2333 ZA Leiden

Postbus 9600
2300 RC Leiden

E-mail: C.Eich@lumc.nl